Although the step-care approach is the current standard of care, this approach is flawed in several ways with respect to achieving optimal outcomes.
Investigators examined whether excessive food allergy testing in patients with atopic dermatitis might lead to food intolerance when certain foods are removed from the diet.
Dupilumab, commonly used for eczema, may be effective for hair regrowth in patients with alopecia totalis and atopic dermatitis.
Dupixent is also being assessed in other allergic/inflammatory conditions, including pediatric atopic dermatitis, pediatric asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, grass allergy, and peanut allergy.
The prevalence of atopic dermatitis is 7.3 percent among U.S. adults, and patients with atopic dermatitis and more severe disease have worse quality of life.
Investigators sought to characterize phenotypic variations in patients with atopic dermatitis who were African American and European American.
Dupilumab reduced cutaneous and systemic measures of inflammation and improved disease-severity scores in 4 weeks in moderate to severe atopic dermatitis.
Few available studies investigated the risk of completed suicide; however, most of these found a positive correlation between AD and completed suicide.
Dermatology Advisor Articles
- Botulinum Toxin Type A Effective for Treating Rosacea Facial Flushing
- Acne Lesions, Scars Treated With Cooling Vacuum-Assisted Erbium:Glass Laser
- Psoriasis Linked With Higher Risk for Sexual Dysfunction
- New Psoriatic Arthritis Guidelines Recommend TNFi as First-Line Tx Option
- AMA Survey Collects Advice for Physicians Approaching Retirement
- Common Skin Conditions in People of Color: Identification and Treatment
- Subcutaneous Dupilumab Initiates Hair Regrowth in Patient With Alopecia Totalis, Atopic Dermatitis
- Rosacea Improves With Anti-Inflammatory Effect of Brimonidine Gel
- Can Examining Marginalization Identify Gaps in Medical or Nutritional Care?
- Mohs Surgery Alone Associated With Improved Outcomes in High-Risk Squamous Cell Carcinoma
- Secukinumab Superior to Placebo for Treatment of Moderate to Severe Nail Psoriasis
- Diagnostic Challenges of Neutrophilic Dermatosis May Lead to Misdiagnosis
- EMS Times Longer for Patients From Poorest Neighborhoods
- Most Insured Patients Not Using Online Portals
- Overcoming the Barriers to Including Pregnant Women in Clinical Trials